Cobalis Corp. Clarifies Recent News Release Citing NAD Review of Advertising Claims

IRVINE, CA--(Marketwire - April 09, 2010) -

On March 9, Cobalis Corp (PINKSHEETS: CLSC) issued a news release announcing its plans to commence its DRTV advertising campaign for its anti-allergy product PreHistin. In this release Cobalis referenced the Company’s participation in a process conducted by the National Advertising Division (NAD) of the Council of Better Business and NAD’s findings. In citing NAD’s decision, Cobalis unintentionally violated NAD’s procedures, which state: “By participating in a NAD/CARU/NARB proceeding, parties agree (a) not to issue a press release regarding any decisions issued, and/or (b) not to mischaracterize any decision issued or use and/or disseminate such decision for advertising and/or promotional purposes.”

Cobalis referenced the NAD findings as newsworthy information and the release was not intended for any advertising or promotional purposes, but nevertheless Cobalis regrets any error or misinterpretation in such usage, and apologizes for any unintentional violations of NAD usage policies. Cobalis Corp. supports self-regulation and the work of the NAD.

ABOUT COBALIS CORP -- PREHISTIN®
Cobalis Corp. is an over the counter pharmaceutical and nutraceutical development company. Its flagship product, “PreHistin®, The World’s FIRST Pre-Histamine"™, is designed to mitigate overproduction of IgE levels, to restore normal response to seasonal and year-round indoor and outdoor allergens and reduce the likelihood of onset of allergy symptoms resulting from histamine release. PreHistin® is available without prescription for both long-term and daily use.

For PreHistin® product information and ordering please visit at http://www.prehistin.com/ or call toll free 1-877-4POLLEN. For additional company information please visit their website at http://www.cobalis.com/.